Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Volumetric Perfusion CT for Early Assessment of Response to Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma

Alexander Sterzik, MD; Melvin D’Anastasi, MD; M. Staehler, MD; Maximilian Reiser, MD; Anno Graser, MD
Departments of Clinical Radiology and Urology, University Hospital Grosshadern, Munich, Germany
|2015-03-10

A 46-year-old male patient, with a right-sided partial nephrectomy due to papillary renal cell carcinoma one year ago, presented with tumor recurrence and new metastases in the right paracolic gutter and right abdominal wall. He was scheduled for anti-angiogenic tyrosin-kinase-inhibitor (TKI) therapy. Serial volumetric perfusion-CT scans of a selected representative metastatic lesion were performed, before as well as seven days after commencement of the anti-angiogenic TKI therapy, for noninvasive monitoring of early treatment response.